March 31, 2025
Innocan Pharma Achieves Record Revenues of US $29.4 Million in Full Year 2024, Doubling Previous Figures
Innocan Pharma Reports Impressive Financial Growth for 2024 HERZLIYA, Israel and CALGARY, AB, March 31, 2025 /CNW/ — Innocan Pharma Corporation INNO IP INNPF (the “Company” or “Innocan“), a pharmaceutical technology firm focused on innovative drug delivery systems, announces its audited consolidated financial results for the year ended December 31, 2024. Financial Highlights for 2024 Revenues surged 114.6% year-over-year to US$29.4 million, rising from US$13.7 million in 2023. This growth was significantly driven by sales from Innocan’s subsidiary, BI Sky Global Ltd. Gross Profit climbed 118.6% year-over-year to US$26.2 million, compared to US$12.0 million in 2023. Operating Loss decreased by